柳藥股份(603368.SH)實控人朱朝陽所持1200萬股非交易過户
格隆匯9月18日丨柳藥股份(603368.SH)公佈,公司控股股東暨實際控制人朱朝陽持有公司股份1.01億股,佔公司目前總股本的27.86%。
為開展股票、基金等金融產品投資,朱朝陽委託國都證券股份有限公司設立“國都證券國鑫2號單一資產管理計劃”,向中國登記結算有限責任公司上海分公司申請辦理證券非交易過户業務,將其所持1200萬股公司股份過户至“國都證券國鑫2號單一資產管理計劃”,作為委託資產由管理人國都證券股份有限公司在相關法律法規和合同規定的權限內進行管理。
本次非交易過户事項及“國都證券國鑫2號單一資產管理計劃”的運作不會導致朱朝陽所持有的公司股份數量發生變化,朱朝陽仍持有公司股份1.01億股,佔公司目前總股本的27.86%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.